Clinical Trial: Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07344948) titled 'Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia' on Nov. 14, 2025.

Brief Summary: This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.

Study Start Date: Oct. 03, 2025

Study Type: INTERVENTIONAL

Condition: Healthy Participants Schizophrenia Diagnosis

Intervention: DRUG: NTX-253

Oral Capsule

DRUG: Placebo

Oral capsule

Recruitment Status: RECRUITING

Sponsor: Neurosterix

Disclaimer: Curated by HT Syndication....